Skip to main content

Hybrigenics, Servier Partner on Deal for Rx, Companion Dx Development

NEW YORK (GenomeWeb News) – French firms Hybrigenics and Servier today announced a licensing and research deal targeting deubiquitinating enzymes, or DUBs, for various diseases that could result in the development of companion diagnostics.

Under the terms of the deal, Hybrigenics will identify and validate new targets among DUBs for cancer, diseases in neurology, psychiatry, rheumatology, and ophthalmology, as well as diabetes, and cardiovascular illness.

It will also screen potential therapeutic agents "able to modulate" four undisclosed targets that have already been chosen as DUBs of interest. Hybrigenics' work, it said, could lead to the discovery of companion diagnostics, "potentially needed for such therapeutic drugs."

Servier will provide the compounds to be screened, as well as develop the selected compounds, and commercialize any approved drugs.

Hybrigenics will receive an upfront payment and research funding totaling €4 million ($5.5 million). If certain milestones are reached, the company could be eligible for an additional €9.5 million for each target that leads to registration of a new drug and to royalties on sales of companion diagnostic kits, it said.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.